An in vitro method for diagnosing whether a subject is at risk for recurrent prostate carcinoma after prostatectomy comprising: (a) determining the amount of at least one metabolite selected from the list consisting of 7-methylguanine, 2-Hydroxybehenic acid, Isopentenyl pyrophosphate, Cerebronic acid (2-OH-C24:0), 14-Methylhexadecanoic acid, 2-Aminoadipinic acid, Ceramide (d18:1, C24:1), Eicosenoic acid (C20:cis 1), Tricosanoic acid (C23:0), Eicosadienoic acid (C20:2) No 02, Arginine, Behenic acid (C22:0), beta-Carotene, Cholestenol No 02, Cytosine, DAG (C18:1, C18:2), Dihydrocholesterol, erythro-Dihydrosphingosine, Docosahexaenoic acid (C22:cis[4,7,10,13,16,19]6), Dodecanol, Eicosanoic acid (C20:0), Eicosapentaenoic acid (C20:cis[5,8,11,14,17]5), Eicosatrienoic acid (C20:3), erythro-C16-Sphingosine, Flavine adenine dinucleotide, gamma-Tocopherol, Gluconic acid, Glucuronic acid, Glycerol-2-phosphate, Lignoceric acid (C24:0), Lysophosphatidylcholine (C18:2), Lysophosphatidylcholine (C20:4), Maltotriose, myo-Inositol (lipid fraction), myo-Inositol-2-phosphate (lipid fraction, myo-Inositolphospholipids), Nervonic acid (C24:cis 1), Nicotinamide, Pentadecanol, Phosphatidylcholine (C18:0, C22:6), Phytosphingosine, Pseudouridine, Pyruvate, 3-O-Methylsphingosine, threo-Sphingosine, 5-O-Methylsphingosine, erythro-Sphingosine, Sphingosine-1-phosphate, Threonic acid, Homoserine, Hypoxanthine, Lysine, Oleic acid (C18:cis 1), and Glycerophosphoethanolamine in a test sample of a subject prior to prostatectomy; and (b) comparing the amount determined in step (a) to a reference, whereby it is diagnosed whether the subject is at risk for recurrent prostate carcinoma after prostatectomy, wherein said at least one metabolite comprises 7-methylguanine, and wherein said test sample is a biopsy sample taken before a planned prostatectomy or the tissue extracted during prostatectomy itself. (a) determining the amount of at least one metabolite selected from the list consisting of 7-methylguanine, 2-Hydroxybehenic acid, Isopentenyl pyrophosphate, Cerebronic acid (2-OH-C24:0), 14-Methylhexadecanoic acid, 2-Aminoadipinic acid, Ceramide (d18:1, C24:1), Eicosenoic acid (C20:cis 1), Tricosanoic acid (C23:0), Eicosadienoic acid (C20:2) No 02, Arginine, Behenic acid (C22:0), beta-Carotene, Cholestenol No 02, Cytosine, DAG (C18:1, C18:2), Dihydrocholesterol, erythro-Dihydrosphingosine, Docosahexaenoic acid (C22:cis[4,7,10,13,16,19]6), Dodecanol, Eicosanoic acid (C20:0), Eicosapentaenoic acid (C20:cis[5,8,11,14,17]5), Eicosatrienoic acid (C20:3), erythro-C16-Sphingosine, Flavine adenine dinucleotide, gamma-Tocopherol, Gluconic acid, Glucuronic acid, Glycerol-2-phosphate, Lignoceric acid (C24:0), Lysophosphatidylcholine (C18:2), Lysophosphatidylcholine (C20:4), Maltotriose, myo-Inositol (lipid fraction), myo-Inositol-2-phosphate (lipid fraction, myo-Inositolphospholipids), Nervonic acid (C24:cis 1), Nicotinamide, Pentadecanol, Phosphatidylcholine (C18:0, C22:6), Phytosphingosine, Pseudouridine, Pyruvate, 3-O-Methylsphingosine, threo-Sphingosine, 5-O-Methylsphingosine, erythro-Sphingosine, Sphingosine-1-phosphate, Threonic acid, Homoserine, Hypoxanthine, Lysine, Oleic acid (C18:cis 1), and Glycerophosphoethanolamine in a test sample of a subject prior to prostatectomy; and (b) comparing the amount determined in step (a) to a reference, whereby it is diagnosed whether the subject is at risk for recurrent prostate carcinoma after prostatectomy, wherein said at least one metabolite comprises 7-methylguanine, and